| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human IL-32-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Gene Symbol: |
IL32 |
| Gene ID: |
9235 |
| Uniprot ID: |
IL32_HUMAN |
| Immunogen Region: |
ECD |
| Immunogen: |
DNA sequence encoding the extracellular domain of Human IL32 including a C-terminal His tag was expressed in HEK293 Cells. NA |
| Immunogen Sequence: |
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTED TVGHLGPWRD KDPALWCQLC LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LETVAAYYEE QHPELTPLLE KERDGLRCRG NA |
| Tissue Specificity | Selectively expressed in lymphocytes. Expression is more prominent in immune cells than in non-immune cells. |
| Function | Cytokine that may play a role in innate and adaptive immune responses. It induces various cytokines such as TNFA/TNF-alpha and IL8. It activates typical cytokine signal pathways of NF-kappa-B and p38 MAPK. |
| Protein Name | Interleukin-32Il-32Natural Killer Cells Protein 4Tumor Necrosis Factor Alpha-Inducing Factor |
| Database Links | Reactome: R-HSA-449836Reactome: R-HSA-9013423 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Interleukin-32 proteinIl-32 proteinNatural Killer Cells Protein 4 proteinTumor Necrosis Factor Alpha-Inducing Factor proteinIL32 proteinNK4 proteinTAIF protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
